PROG
-
x
x
bid
ask
07:48 AM
Bearish
28
Bullish
90
sentiment
0.00
day range
0.00
0.00
52 week range
0.00
News
...
Profile
...
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-05-10 | 2022-03 | -0.12 | N/A | N/A | N/A |
2022-03-28 | 2021-12 | -0.13 | N/A | N/A | N/A |
2021-11-10 | 2021-09 | -0.47 | N/A | N/A | N/A |
2021-08-12 | 2021-06 | -0.8 | N/A | N/A | N/A |
2021-05-13 | 2021-03 | -0.83 | N/A | N/A | N/A |
2021-03-18 | 2020-12 | -0.76 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2021-10-14 | HC Wainwright & Co. | Upgrade | Buy | |
2021-06-03 | Raymond James | Downgrade | Outperform | Market Perform |
2021-06-03 | Baird | Downgrade | Outperform | Neutral |
2021-05-17 | Wells Fargo | Upgrade | Underweight | |
2021-05-14 | Raymond James | Upgrade | Outperform | |
2021-02-08 | Wells Fargo | Downgrade | Overweight | Underweight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-06-13 | ATHYRIUM OPPORTUNITIES FUND A, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2021-06-13 | BIGALKE JOHN T | Director | 47.52K | Stock Award(Grant) |
2022-04-14 | D'ESPARBES ERIC | Chief Financial Officer | 423.17K | Stock Award(Grant) |
2021-11-02 | HOWE JILL ANN | Director | 76.75K | Stock Award(Grant) |
2021-06-13 | KOTZIN BRIAN L | Director | 47.52K | Stock Award(Grant) |
2021-11-07 | MOHANTY ADITYA P | Chief Executive Officer | 1.41M | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-12-30 | Athyrium Capital Management, LP | 29.86M | 62.40M | 16.21% |
2022-03-30 | Neuberger Berman Group, LLC | 6.54M | 7.59M | 3.55% |
2022-03-30 | Vanguard Group, Inc. (The) | 5.16M | 5.98M | 2.80% |
2022-03-30 | Blackrock Inc. | 1.66M | 1.93M | 0.90% |
2022-03-30 | Geode Capital Management, LLC | 1.15M | 1.34M | 0.63% |
2022-03-30 | Susquehanna International Group, LLP | 955.32K | 1.11M | 0.52% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-12-30 | Vanguard Total Stock Market Index Fund | 3.03M | 6.32M | 1.64% |
2021-12-30 | Vanguard Extended Market Index Fund | 1.58M | 3.29M | 0.86% |
2022-02-27 | Fidelity Extended Market Index Fund | 615.33K | 830.69K | 0.33% |
2022-02-27 | Fidelity Total Market Index Fund | 210.77K | 284.53K | 0.11% |
2022-02-27 | Fidelity Series Total Market Index Fund | 121.33K | 163.79K | 0.07% |
2022-02-27 | Fidelity NASDAQ Composite Index Fund | 80.80K | 109.08K | 0.04% |
This topic has been deleted. Only users with topic management privileges can see it.
-
Huge w forming like this morning run up
-
-
If this holds and the MACD has a CROSS up on the Five Day this could go to 3
-
When is the PR ? Isn’t the patent already approved yesterday???
-
Recovering
Let’s get back to 2.5 before lunch time over
-
SLAP THE ASK!!
-
Forming a HUGE W
-
Stock is going 10, if you hate you a bear ahhahaahahah
-
Bought 10 000 more
-
Cross down on the five day!! RUNNN OUT OF HEREEE
-
10!$$ easyyyy
-
Hold strong through the lunch hour
We will recover post lunch and rocket in PH and AH
-
I’m not worried or stressed. Is that bad? It feels wonderful to have such confidence!
Oi! Prob just jinxed meself
-
Downtrend?
-
LOOK AT THE FIVE DAY!!! It needs to cool
Off. -
When is the PR coming ?
-
NO MORE SHORTIES BUYYY
-
3$!!!!! Yes
-
Hold
We are getting to 3 minimum
-
Bullish W
-
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
globenewswire.com • -
Progenity to Become Biora Therapeutics as it Completes Transformation
globenewswire.com • -
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
globenewswire.com • -
Should You Invest in These Penny Stocks Next Month? 3 to Watch
pennystocks.com • -
Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch This Week
pennystocks.com • -
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
globenewswire.com • -
Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February
pennystocks.com • -
Top Reddit Penny Stocks That Investors Are Watching Right Now
pennystocks.com • -
3 Penny Stocks Climbing During Today's Trading Session
pennystocks.com • -
These 4 Penny Stocks Exploded Today, Here's Why
pennystocks.com • -
Here's 3 Trending Penny Stocks to Add to Your Watchlist in February
pennystocks.com • -
5 Top Penny Stocks To Buy Now According To Reddit
pennystocks.com •